The findings were notable: among participants without type 2 diabetes , those receiving the highest dose (12 mg) achieved a mean body weight reduction of approximately 24% over 48 weeks
All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes
Food and Drug Administration, FDA, 8 Nov
Jayne Hornung, chief clinical officer at Managed Markets Insight and Technology, suggests initial pricing of oral GLP-1s for weight loss could be reminiscent of the early days of anti-CGRP medications for migraines when the first oral CGRP came to market in 2019, the pricing still remained high
Last reviewed: July 2, 2026 Last updated: July 2, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The guidelines also recommend using the medication in patients with a compelling need to minimize weight gain, patients prone to hypoglycemia, and patients who need a substantial A1C reduction [38]
